Company intelligence / Profile preview

Relive Health

Newton, Massachusetts, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Spherox (autologous chondrocyte implant) is approved by EMA for treatment of knee cartilage, used in >17,000 patients, with Phase II/III data supporting efficacy and safety. New universal cell therapy and stem cell plus scaffold technologies in preclinical development.

Therapeutic areas: OtherRheumatology
Modalities: Cell therapyAutologous cell therapyStem cell therapyTissue engineering
Industry: Biotech

Partnerships

Shanghai Healthcare Capital (SHC) (investment & strategic support)Partnership/funding with Indaco Capital, Jiuyo Capital, Watson CapitalR&D collaborations with Harvard, MIT, research institutes in China, U.S., EU

Beyond the preview

Go deeper on Relive Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Relive Health.

Explore the full profile